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Summary
BACKGROUND: Healthcare workers are more frequently
exposed to SARS-CoV-2 than the general population. Lit-
tle is known about healthcare settings outside of hospitals.
We studied the seroprevalence of SARS-CoV-2 among
healthcare workers in outpatient facilities and retirement or
nursing homes in the Canton of Solothurn, Switzerland in
the first wave of the COVID-19 pandemic.
METHODS: Longitudinal seroprevalence study among
healthcare workers with examinations at baseline and 2
months between June and September 2020. The Abbott
SARS-CoV-2 IgG and Liaison/Diasorin SARS-CoV-2 S1/
S2 IgG assay were used to detect antibodies against
SARS-CoV-2. All participants provided demographic infor-
mation. We report descriptive statistics and calculated the
seroprevalence with 95% confidence intervals.
RESULTS: We included 357 healthcare workers; their me-
dian age was 43 years (interquartile range 29–54), and
315 (88.2%) were female. Forty-nine (13.7%) were physi-
cians, 87 (24.4%) practice assistants and 221 (61.9%)
nurses. Overall seroprevalence among healthcare work-
ers in outpatient facilities and retirement or nursing homes
was 3.4% (12/357). The 12 seropositive healthcare work-
ers were all nurses (12/221, 5.5%); 11 worked at retire-
ment or nursing homes and one at the hospital's outpatient
clinic. Symptoms such as loss of smell or taste, shortness
of breath, and fever were more prevalent among seropos-
itive healthcare workers than seronegative healthcare
workers. No close contact had detectable antibodies
against SARS-CoV-2.
CONCLUSIONS: Seroprevalence among healthcare
workers was low, but higher among nursing staff of re-
tirement or nursing homes. Healthcare workers at private
practices were able to protect themselves well during the
first wave of the COVID-19 pandemic.
Introduction
The emergence and rapid spread of the novel severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2), which
causes coronavirus disease 2019 (COVID-19) has
achieved a pandemic scale. In Switzerland, as of 1 June
2020, more than 32,092 people had tested positive for
SARS-CoV-2, and 1728 people had died from COVID-19
[1].
The primary mode of infection of SARS-CoV-2 involves
the respiratory transmission of mouth and nose secretions
via direct and indirect contact with infected people; touch-
ing the face after touching contaminated surfaces is a sec-
ondary mode of transmission. Healthcare workers have an
increased risk of SARS-CoV-2 infection because of their
close contact with highly infectious patients and their ex-
posure to undiagnosed or subclinical infectious persons. In
Italy, 8% of all healthcare workers in hospital settings had
a positive serological test; a corresponding figure in Spain
was 11% and in southern Switzerland 10% during the first
wave [2–5]. The high prevalence among healthcare work-
ers in Italy, Spain or southern Switzerland might be be-
cause these regions were initially overwhelmed by the pan-
demic early during the first wave when the pathogen was
less well described.
The current state-of-the-art for diagnosing acute SARS-
CoV-2 infection uses a real-time reverse transcriptase
polymerase chain reaction (rRT-PCR) to detect viral ge-
netic material on nasopharyngeal swabs [6]. Serological
tests, in contrast, detect antibodies against the virus, which
persist after the infection [7, 8]. However, both methods
are time-dependent. rPCR reliably detects viral DNA early,
during the first week after infection, whereas serological
antibody tests produce positive results only 5 to 7 days af-
ter infection [9, 10], rendering them unreliable for diagnos-
ing acute infection. A key feature of serological tests is that
they can detect prior infection for a longer time period [11].
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The Canton of Solothurn is a mid-sized canton in Switzer-
land, which was moderately affected by the first wave (01
January to 30 June 2020) of the COVID-19 pandemic. It
is unknown how well healthcare workers were able to pro-
tect themselves during the first wave of the epidemic. We
studied the seroprevalence of SARS-CoV-2 in Switzerland
among healthcare workers in the Canton of Solothurn's
outpatient facilities and retirement or nursing homes and
among their close contacts.
Methods
Study design and inclusion criteria
This was a longitudinal seroprevalence study among
healthcare workers in outpatient facilities and retirement
or nursing homes in the Canton of Solothurn, Switzerland,
with two examination time-points (baseline and 2 months
later). The cohort consisted of healthcare workers with a
minimum workload of ≥50% who worked in the outpatient
clinic at a hospital, medical practice, retirement or nursing
home, or in home care, who were at least 18 years old and
had contact with patients before and during the first SARS-
CoV-2 epidemic wave from 1 January to 30 June 2020.
The degree of patient contact depends on the workplace.
At baseline (time point 0, which was between 1 June and
1 July 2020), participants completed a questionnaire and a
blood sample was taken by a healthcare professional at the
facility; if the result was positive another blood sample was
taken 2 months later.
In addition, persons in close contact from the same house-
hold as the HCW who tested positive for SARS-CoV-2
by serology, were also invited to participate in this study.
These close contacts also completed the questionnaire and
were invited to have a blood sample taken.
Selection of the study sites
To encompass the spectrum of outpatient care facilities in
the Canton of Solothurn, we included outpatient clinics at
the hospitals, medical practices and home care organisa-
tions in this study. In addition, we included retirement or
nursing homes. These sites included a secondary referral
hospital in the canton, where COVID-19 patients are treat-
ed. We included all of the medical practices that performed
SARS-CoV-2 testing, a sample of medical practices that
did not test for SARS-CoV-2 and a convenience sample of
paediatric practices. We chose a representative sample of
retirement or nursing homes by size (small and large) and
location. Similar sampling strategies were applied for the
homecare organisations. For each of the participating out-
patient care facilities and retirement or nursing homes, we
invited all healthcare workers to participate in the study ac-
cording to the inclusion criteria.
Data collection
We developed and pilot-tested a questionnaire in collabo-
ration with the participants. The paper-based questionnaire
had three sections: (i) basic information such as sex, age,
profession, workload, healthcare facility; (ii) episodes of
illness including date, symptoms, testing for SARS-CoV-2,
self-isolation and quarantine; (iii) travel including date and
destination. Questionnaire data were entered into REDCap
by a single person [12, 13].
A blood sample was taken from each participant and cen-
trally processed and stored at the Institute of Laboratory
Medicine in Olten. Analyses were made at the Institute
for Infectious Diseases (IFIK) of the University of Bern.
Blood samples were run on the Abbott ARCHITECT
i2000 instrument using the Abbott SARS-CoV-2 IgG assay
(Abbott Diagnostics, Chigago, US) and the Liaison SARS-
CoV-2 S1/S2 IgG assay (DiaSorin, Saluggia, Italy) follow-
ing the manufacturer’s instructions. The Abbott assay is a
chemiluminescent microparticle immunoassay for qualita-
tive detection of IgG in human serum or plasma against the
SARS-CoV-2 nucleoprotein [8]. The Liaison SARS-CoV-2
S1/S2 is a chemiluminescence assay consisting of para-
magnetic microparticles coated with S1 and S2 fragments
of the viral surface spike protein. It is used for the qualita-
tive detection of IgG in human serum or plasma against the
SARS-CoV-2 [7].
Definitions
We defined COVID-19 seropositivity as having a positive
Abbott SARS-CoV-2 IgG or Liaison SARS-CoV-2 S1/S2
IgG assay, to increase the sensitivity. The two assays detect
antibodies against two different components of the virus.
The nursing profession in Switzerland includes three
groups of HCW. The level 1 nurse assistant is a nurse with
a short education on basic care. The level 2 nurse assistant
is a nurse with 3 years of education who works under the
direction of a qualified nurse. The qualified nurse is a nurse
with 4 years of education at a university of applied science.
Statistical analyses
We used descriptive statistics to characterise the study pop-
ulation by seroprevalence. Differences between groups
were assessed using chi‐square, Fisher's exact, or Wilcox-
on rank‐sum tests. We calculated the seroprevalence with
the corresponding 95% confidence interval (CI). All analy-
ses were done in Stata (version 15.1, College Station, TX,
USA).
Ethics statement
The Cantonal Ethics Committee Nordwestschweiz
(Switzerland) approved this study (project ID no.
2020-01004). Written informed consent was obtained from
all participants.
Results
We drew upon 26 healthcare facilities: 12 medical prac-
tices, 11 retirement or nursing homes, one hospital outpa-
tient clinic, and two homecare organisations (see supple-
mentary table S1 in the appendix). More information about
the health care facilities can be found in table S1.
Full-time equivalents were lower for homecare than retire-
ment or nursing homes (67.5% vs 90%). Overall, median
contact with patients among the different healthcare facili-
ties was around 30 hours per week and 23 hours per week
for home care.
Healthcare worker characteristics
We included 357 healthcare workers. Their median age
was 43 years (interquartile range [IQR] 29–54), and 315
were women (88.2%, table 1). Across all healthcare work-
ers, 169 (47.3%) were based in retirement or nursing
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homes, 118 (33.1%) in medical practices, 42 (11.8%) at the
hospital, and 28 (7.8%) in home care. A majority of nurs-
es worked in homecare or retirement or nursing homes,
whereas the physicians and medical assistants worked at
medical practices or the hospital (table 1, supplementary
table S2).
Overall, the uptake of the 2019/20 seasonal influenza vac-
cination was 33.3% (119/357). Influenza vaccine uptake
was high among physicians, at 85.7% (42/49), and lowest
among nurses, at 21.7% (48/221, table 1).
Seroprevalence among healthcare workers
We identified 12 seropositive persons among the 357
healthcare workers (3.4%, 95% Cl 1.7–5.8%). All were
among the 221 nursing staff, giving a respective sero-
prevalence of 5.4% (95% CI 2.8–9.3%, table 2, fig. 1A).
The median age of the seropositive healthcare workers
was 43 years (IQR 29–54), and all were women (table
2). Seven out of 34 level 1 nurse assistants (20.6%) were
seropositive, as were three out of 73 level 2 nurse assistants
(4.1%), and two out of 117 qualified nurses (1.7%) (table
1, fig. 1B). Eleven of the 12 seropositive healthcare work-
ers worked at a retirement or nursing home, a seropreva-
lence of 6.5% (11/169, 95% Cl 3.3–11.3%). The other
seropositive HCW worked at the hospital, a seroprevalence
of 2.4% (1/42, 95% Cl 0.1–12.6%) among hospital partic-
ipants (fig.1B, table S2). Three of the seropositive health-
care workers were asymptomatic and nine symptomatic
(tables2 and 3). Among the nine reporting symptoms, the
most frequently mentioned symptoms were fever 6/9
(66.7%), 6/9 (66.7%) headache, 5/9 (55.6%) muscle and
body aches, 4/9 (44.4%) shortness of breath and 3/9
(33.3%) cough. In addition, loss of smell or taste were
mentioned by 2/9, (22.2%) of healthcare workers (table 3).
Symptoms such as loss of smell or taste, or shortness of
breath were more prevalent among seropositive healthcare
workers than among seronegative healthcare workers (p
Table 1:
Characteristics of study participants by profession (n = 357).
Total Physician Practice assistant Nurse
Any nurse Qualified nurse Nurse assistant level 2 Nurse assistant level 1
n = 357 n = 49 n = 87 n = 221 n = 114 n = 73 n = 34
Sex
Male 42 (11.8) 22 (44.9) 2 (2.3) 18 (8.1) 7 (6.1) 7 (9.6) 4 (11.8)
Female 315 (88.2) 27 (55.1) 85 (97.7) 203 (91.9) 107 (93.9) 66 (90.4) 30 (88.2)
Age (years), median (IQR) 43 (29–54) 44 (38–49) 32 (25–47) 51.5 (39–59) 30 (22–49) 48 (38–57)
Number of observations 357 49 87 221 114 73 34
Healthcare facilities
Hospital 42 (11.8) 7 (14.3) 16 (18.4) 19 (8.6) 13 (11.4) 4 (5.5) 2 (5.9)
Medical practice 118 (33.1) 42 (85.7) 69 (79.3) 7 (3.2) 7 (6.1) 0 0
Retirement or nursing home 169 (47.3) 0 1 (1.1) 168 (76.0) 82 (71.9) 59 (80.8) 27 (79.4)
Homecare 28 (7.8) 0 1 (1.1) 27 (12.2) 12 (10.5) 10 (13.7) 5 (14.7)
Illness
Yes 150 (42.0) 24 (49.0) 29 (33.3) 97 (43.9) 48 (42.1) 33 (45.2) 16 (47.1)
No 207 (58.0) 25 (51.9) 58 (66.7) 124 (56.1) 66 (57.9) 40 (54.8) 18 (52.9)
Self-reported symptoms
Yes 150 (42.0) 24 (49.0) 29 (33.3) 97 (43.9) 48 (42.1) 33 (45.2) 16 (47.1)
Fever 42 (11.8) 2 (4.1) 8 (9.2) 32 (14.5) 13 (11.4) 12 (16.4) 7 (20.6)
Cough 84 (23.5) 15 (30.6) 16 (18.4) 53 (24.0) 27 (23.7) 20 (27.4) 6 (17.6)
Shortness of breath or difficulty breathing 26 (7.3) 1 (2.0) 0 25 (11.3) 10 (8.8) 12 (16.4) 3 (8.8)
Muscle or body aches 51 (14.3) 8 (16.3) 9 (10.3) 34 (15.4) 16 (14.0) 11 (15.1) 7 (20.6)
Loss of taste or smell 7 (1.9) 0 1 (1,1) 6 (2.7) 2 (1.8) 3 (4.1) 1 (2.9)
Headache 70 (19.6) 9 (18.4) 10 (11.5) 51 (23.1) 27 (23.7) 18 (24.7) 6 (17.6)
Congestion or runny nose 68 (19.0) 18 (36.7) 14 (16.1) 36 (16.3) 20 (17.5) 12 (16.4) 4 (11.8)
Diarrhoea 7 (1.9) 1 (2.0) 1 (1.1) 5 (2.3) 1 (0.9) 2 (2.7) 2 (5.9)
Sore throat 12 (3.4) 1 (2.0) 1 (1.1) 10 (4.5) 4 (3.5) 3 (4.1) 3 (8.8)
No 207 (58.0) 25 (51.0) 58 (66.7) 124 (56.1) 66 (57.9) 40 (54.8) 18 (52.9)
Influenza vaccination 2019/20
Yes 119 (33.3) 42 (85.7) 29 (33.3) 48 (21.7) 27 (23.7) 10 (13.7) 11 (32.4)
No 237 (66.4) 7 (14.3) 58 (66.7) 172 (77.8) 86 (75.4) 63 (86.3) 23 (67.7)
Unknown 1 (0.3) 0 0 1 (0.5) 1 (0.9) 0 0
Quarantine
Yes 8 (2.2) 2 (4.1) 0 5 (2.3) 0 4 (5.5) 1 (2.9)
No 349 (97.8) 47 (95.9) 0 216 (97.7) 114 (100) 69 (94.5) 33 (97.1)
Self-isolation
Yes 14 (3.9) 1 (2.0) 2 (2.3) 11 (5.0) 2 (1.7) 5 (6.8) 4 (11.8)
No 343 (96.1) 48 (98.0) 85 (97.7) 210 (95.0) 112 (98.3) 68 (93.2) 30 (88.2)
Seroprevalence
Number of seropositive persons 12 0 0 12 2 3 7
Percent (95% Cl) 3.4 (1.7–5.8) 0 0 5.4 (2.8–9.3) 1.7 (0.2–6.2) 4.1 (0.9–11.5) 20.6 (8.7–37.9)
CI = confidence interval; IQR = interquartile rangeData are n (%) unless otherwise indicated.
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<0.05). Only two of the 12 healthcare workers were tested
for SARS-CoV-2 by PCR, one with a positive and one with
a negative result. Half of seropositive healthcare work-
ers (6/12, 50.0%) reported having been self-isolating and
16.7% (2/12) were in self-quarantine. Seropositive health-
care workers reported more frequently having been in self-
isolation or self-quarantine than seronegative healthcare
workers (self-isolation 50.0% vs 2.3%, p <0.001; self-
quarantine 1.7% vs 16.7%, p <0.001, table 2).
Serological results
Among the 12 seropositive healthcare workers, seven
(58.3%) had both serological tests (Abbott ARCHITECT
i2000 and Liaison SARS-CoV-2 S1/S2 IgG) positive, three
(25.0%) only the liaison SARS-CoV-2 S1/S2 IgG and the
remaining two (16.7%) only the Abbott ARCHITECT
i2000 in the first blood sample. In the second blood sam-
ple, one (8.3%) HCW had both serological tests positive,
three (25.0%) only the liaison SARS-CoV-2 S1/S2 IgG,
two (16.7%) only the Abbott ARCHITECT i2000 and the
remaining six (50.0%) did not provide a second sample. In
healthcare workers with two samples, we observed a de-
cline of the signal (index) in the ARCHITECT nucleocap-
sid targeting assay in five. Both assays (S1/S2 and N) were
congruently positive above 93 relative units (Liason; S1/
S2) rand above an index of 4.8 (ARCHITECT; N). De-
tails on the serology results from the first and second blood
samples can be found in table 3.
Among the 12 seropositive healthcare workers, six lived
alone and reported no close contacts in a home setting,
while the remaining six had one to three close contacts at
home for a total of ten close contacts. None of them had
a positive serology result during this study. Among the ten
close contacts three (30.0%) self-quarantined.
Discussion
The overall seroprevalence among healthcare workers in
outpatient settings and retirement or nursing homes in the
Canton of Solothurn, Switzerland, was low at 3.4%. How-
ever, seroprevalence among these healthcare workers has
interesting characteristics. All 12 of the seropositive
healthcare workers were nursing staff, 11 of whom worked
in retirement or nursing homes. Among these seropositive
nursing participants, prevalence fell with level increasing
nursing skills and associated character of patient involve-
ment. At 21%, seroprevalence was highest among the level
1 nurse assistants, followed by a prevalence of 4% among
the level 2 nurse assistants and 1.7% among the qualified
Figure 1: eSARS-coV-2 seroprevalence by (A) workplace and (B) among nurses (homecare, outpatient departments of the hospital, nursing
homes). There were no events in the categories “medical practices” and “homecare”.
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nurses. As expected, the characteristic symptoms, such
as loss of smell or taste, shortness of breath, and fever,
were more common among seropositive than seronegative
healthcare workers, indicating the serological results of
true positive, previously undiagnosed COVID-19 infec-
tions.
At the beginning of the pandemic, the supply of personal
protective equipment (PPE), such as protective clothing,
masks, and gloves, was limited in Switzerland. PPE was
primarily provided to hospitals and medical practices treat-
ing confirmed COVID-19 patients or performing
COVID-19 testing. The supply of PPE was often insuffi-
cient at retirement or nursing homes. This was also the case
in other countries where COVID-19 outbreaks were report-
ed at retirement or nursing homes. These studies reported
attack rates of 40% to 72% among nursing home residents
[14–18]. Infection rates among staff members ranged from
1.5% to 5.9% in studies where all staff were routinely test-
ed during an outbreak [17, 19, 20].
Imperfect use of PPE and infection prevention and control
measures (IPCs) among healthcare workers increases their
risk of infection and potential transmission of the virus
through daily interactions with patients and staff [16, 21].
This might particularly be true in for nursing homes and
home care organisations, where IPC expertise is generally
lower than in the hospital setting or medical practices, and
where balancing the preservation of a home-like environ-
ment and the adoption of IPC measures is challenging [22].
A Swiss study in retirement or nursing homes showed that
only 52% of the institutions provided regular hand hygiene
training [23]. On the other hand, patient contact is likely to
be longer and more intensive among healthcare workers in
nursing homes. These factors might have contributed to the
higher seroprevalence at retirement or nursing homes com-
Table 2:
Characteristics by serology status.
Total Seronegative Seropositive p-value
n = 357 n = 345 n = 12
Sex 0.37
Male 42 (11.8) 42 (12.2) 0
Female 315 (88.2) 303 (87.8) 12 (100)
Age (years) median (IQR) 43 (29-54) 48 (26.5-61.5) 43 (29-54) 0.47
Profession <0.001
Physician 49 (13.7) 49 (14.2) 0
Any nurse 221 (61.9) 209 (60.6) 12 (100)
Qualified nurse 114 (31.9) 112 (32.5) 2 (16.7)
Nurse assistance level 2 73 (20.5) 70 (20.3) 3 (25.0)
Nurse assistance level 1 34 (9.5) 27 (7.8) 7 (58.3)
Practice assistant 87 (24.4) 87 (25.2) 0
Institution 0.012
Hospital 42 (11.8) 41 (11.9) 1 (8.3)
Medical practice 118 (33.1) 118 (34.2) 0
Retirement or nursing home 169 (47.3) 158 (45.8) 11 (91.7)
Homecare 28 (7.8) 28 (8.1) 0
Illnesses, self-reported since 1 Jan. 2020 0.03
Yes 150 (42.0) 141 (40.9) 9 (75.0)
No 207 (58.0) 204 (59.1) 3 (25.0)
Symptoms 0.03
Yes 150 (42.0) 141 (40.9) 9 (75.0)
Fever 42 (11.8) 36 (10.4) 6 (50.0) 0.08
Cough 84 (23.5) 81 (23.5) 3 (25.0) 0.16
Shortness of breath or difficulty breathing 26 (7.3) 22 (62.9) 4 (33.3) 0.03
Muscle or body aches 51 (14.3) 47 (13.6) 5 (41.7) 0.50
Loss of taste or smell 7 (1.9) 5 (1.4) 2 (16.7) 0.01
Headache 70 (19.6) 64 (18.6) 6 (50.0) 0.22
Congestion or runny nose 68 (19.0) 65 (18.8) 3 (25.0) 0.46
Diarrhoea 7 (1.9) 7 (2.0) 0 0.49
Sore throat 12 (3.4) 12 (3.5) 0 0.36
No 207 (58.0) 204 (59.1) 3 (25.0)
Vaccination against influenza 2019/20 0.99
Yes 119 (33.3) 115 (33.3) 4 (33.3)
No 237 (66.4) 229 (66.4) 8 (66.7)
Unknown 1 (0.3) 1 (0.3) 0
Self-quarantine <0.001
Yes 8 (2.2) 6 (1.7) 2 (16.7)
No 349 (97.8) 339 (98.3) 10 (83.3)
Self-isolation <0.001
Yes 14 (3.9) 8 (2.3) 6 (50.0)
No 343 (96.1) 337 (97.7) 6 (50.0)
IQR = interquartile rangeData are n (%) unless otherwise indicated.
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pared with medical practices. With clear communication,
a strong safety climate, access to PPE, regular staff train-
ing and involvement of all staff members in the implemen-
tation, the adherence to IPCs is increased [24, 25]. In the
Canton of Solothurn, major efforts were undertaken during
the first wave to train and support nursing homes in pre-
vention measures, including online tutorials and webinars,
counselling by IPC experts and supply of PPE.
Several studies have shown that healthcare workers, espe-
cially nurses, have a higher seroprevalence than the gen-
eral population [26, 27]. In our study, only nurses were
seropositive and seroprevalence declined with higher lev-
els of nursing education. Our findings are in line with a
large, hospital-based study in Sweden, which found the
highest seroprevalence among assistant nurses, followed
by qualified nurses and medical doctors [28]. In Switzer-
land, nurse assistants at levels 1 and 2 are mainly respon-
sible for patients’ personal care, such as washing, going to
the toilet or getting dressed. In contrast, qualified nurses
have different responsibilities, such as preparing medica-
tions for patients and being more involved in administra-
tive tasks.
Asymptomatic healthcare workers might play a role in
transmitting SARS-CoV-2 to residents, patients or family
members [29]. In our study, 25% of the seropositive
healthcare workers were asymptomatic. A study in a large
teaching hospital in Wuhan found that infections were
asymptomatic in 9.7% of healthcare workers [30, 31].
Of particular interest, in addition to the finding of an in-
creased seroprevalence in nurses with the closest and most
prolonged contact with patients, was the finding of no
seropositive front-line healthcare workers treating patients
with respiratory symptoms and taking nasopharyngeal
swabs from suspected cases. These findings support the
conclusion that the use of PPE renders sufficient protection
during contact limited in terms of time and physical dis-
tance with a suspected SARS-CoV-2 index case. A previ-
ous study in the Canton Solothurn has shown that even in
the absence of PPE, limited contact with an oligosympto-
matic index case resulted in no detectable secondary cas-
es [32]. Therefore the cumulative exposure time and the
intensity of physical contact, in combination with conse-
quent PPE, seem to be the most prominent factors, ren-
dering short contacts in the ambulatory healthcare sector
safe even when undertaking diagnostic procedures in
COVID-19 suspects.
This study has several limitations. The number of seropos-
itive healthcare workers was low, and therefore, we could
not use analytical statistics to examine risk factors. Partic-
ipation in this study was voluntary, and we do not know
Table 3:
Characteristics of the twelve study participants seropositive for SARS-CoV-2.














Value Inter. Value Inter. Value Inter. Value Inter





No – 0.02 Negative 22.5 Positive





Yes Fever, cough, shortness of breath difficulty
breathing, muscle or body aches,
headache
4.64 Positive 105 Positive






Yes Fever, cough, muscle or body aches, loss
of taste or smell, headache, congestion or
runny nose
2.10 Positive 54.5 Positive






Yes Fever, shortness of breath or difficulty
breathing, headache
Negative 1.87 Positive 3.8 Negative 1.82 Positive 3.8 Negative






Yes Shortness of breath or difficulty breathing,
loss of taste or smell, headache
0.71 Negative 55.4 Positive






Yes Muscle or body aches, headache 7.13 Positive 68.4 Positive 6.06 Positive 146 Positive
7 F 41 Hospital Nurse as-
sistant lev-
el 1
Yes Fever 3.88 Positive 10.3 Negative 2.95 Positive 5.7 Negative






Yes Fever, shortness of breath or difficulty
breathing, muscle or body aches
1.57 Positive 27.6 Positive 0.71 Negative 63.1 Positive






Yes Fever, cough, congestion or runny nose 1.11 Negative 44 Positive






Yes Headache, congestion or runny nose,
sore throat
Positive 2.86 Positive 60.4 Positive 0.96 Negative 70.1 Positive






No – 2.15 Positive 50.1 Positive 1.17 Negative 78.9 Positive






No – 1.87 Positive 20.4 Positive
Inter. = interpretation; PCR = polymerase chain-reaction test
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the serological status of those who chose not to participate.
Another limitation pertains to the fact that serological tests
may show cross-reactivity with other coronaviruses. Final-
ly, our study may underestimate or overestimate the sero-
prevalence among healthcare workers. Even though we
can not be sure how representative of the true seropreva-
lence our results are, this study’s strength is that outpatient
and long-term care facilities included in the survey are rep-
resentative of the Canton of Solothurn.
Conclusions
The overall seroprevalence among healthcare workers after
the first wave was low in outpatient and nursing home set-
tings in Switzerland. However, HCW seropositivity was
increased in retirement or nursing homes, and furthermore
increased with the nurse assistants’ responsibilities, possi-
bly due to increased patient contact. Healthcare workers at
private practices could protect themselves sufficiently dur-
ing the first wave of the COVID-19 pandemic.
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Appendix: Supplementary tables
Table S1:
Capacity of the individual healthcare facilities participating in the study (n = 26) during first wave of the COVID-19 pandemic.
Median (IQR)
Medical practice, n 12
Number of patients per week 150 (50–410)
Number of practise assistant 7 (5–12)
Number of physicians 5 (3–6)
Workload 80 (60–100)
Patient contact in hours per week 32.5 (22.5–40)
Retirement or nursing home, n 11
Number of residents 63 (24–82)
Number of health workers 47 (26–80)
Number of other employees 37 (11–43)
Workload 82.5 (75–100)
Patient contact in hours per week 32 (25–40)
Homecare organisation, n 2
Number of people cared by organisation 106 (50–159)
Number of health care professionals per organisation 23 (11–29)
Number of people cared by nurse per week 19 (15–20)
Workload 67.5 (60–85)
Patient contact in hours per week 23 (18–29)
Hospital outpatient clinic, n 1
Number of patients per week 55 (31–100)
Number of medical doctors in the clinic 6 (6–9)
Number of nurses in the clinic 15 (12–15)
Workload 80 (60–100)
Patient contact in hours per week 30 (18–35)
IQR = interquartile range
Table S2:
Characteristics by healthcare facility (n = 357).
Total Hospital Medical practice Retirement or nursing home Homecare
n = 357 n = 42 n = 118 n = 169 n = 28
Sex
Male 42 (11.8) 5 (11.9) 20 (16.9) 17 (10.1) 0
Female 315 (88.2) 37 (88.1) 98 (83.1) 152 (89.9) 28 (100)
Age (years), median (IQR) 43 (29–54) 39 (32–48) 39 (28–49) 46 (28–57) 49 (38.5–55.5)
Profession
Physician 49 (13.7) 7 (16.7) 42 (35.6) 0 0
Adults 40 (11.2) 7 (16.7) 33 (28.0) 0 0
Children 9 (2.5) 0 9 (7.6) 0 0
Any nurse 221 (61.9) 19 (45.2) 7 (5.9) 168 (99.4) 27 (96.4)
Qualified Nurse 114 (31.9) 13 (31.0) 7 (5.9) 82 (48.5) 12 (42.9)
Nurse assistance level 2 73 (20.5) 4 (9.5) 0 59 (34.9) 10 (35.7)
Nurse assistance level 1 34 (9.5) 2 (4.8) 0 27 (16.0) 5 (17.9)
Practice assistant 87 (24.4) 16 (38.1) 69 (58.5) 1 (0.6) 1 (3.6)
Employment (percentage of FTE) 80 (60–100) 80 (60–100) 80 (60–100) 90 (80–100) 67.5 (60–85)
Number of observations 356 41 118 169 28
Contact with patients (hours/week), median (IQR) 30 (22–40) 30 (17–35.5) 33 (23–40) 32 (25–40) 23 (18–26)
Number of observations 311 40 111 137 23
Seroprevalence
Number of seropositive persons 12 1 0 11 0
Percent, 95% Cl 3.4 (1.7–5.8) 2.4 (0.1–12.6) 0 6.5 (3.3–11.3) 0
CI = confidence interval; FTE = full time equivalent; IQR = interquartile rangeData are n (%) unless otherwise indicated.
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